このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Aptahem マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Mikael Lindstam

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	0.1%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	4.5yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Mikael Lindstam (58 yo)

no data

在職期間

Mr. Mikael Lindstam served as Director at Cyxone AB (publ) since 2015 until May 30, 2023 and served its Chief Operating Officer. Mr. Lindstam is Co-Founder of Aptahem AB (publ) and serves as the Chief Exec...

取締役

名称	ポジション	在職期間	報酬	所有権
Bert Junno	Co-Founder & Chairman of the Board	4.5yrs	データなし	データなし
Theresa Comiskey Olsen	Director	no data	データなし	0.041% SEK 6.9k
Christina Glad	Director	8yrs	データなし	0.016% SEK 2.7k
Jan Nilsson	Director	2.5yrs	データなし	データなし
Asa Kornfeld	Director	2.5yrs	データなし	データなし
Johan Lindh	Director	no data	データなし	0.095% SEK 16.0k
Anders Bylock	Chairman of the Scientific Advisory Board	8.5yrs	データなし	データなし
Mats Eriksson	Member of Scientific Advisory Board	no data	データなし	データなし

4.5yrs

平均在職期間

66.5yo

平均年齢

経験豊富なボード: APTAの取締役会は経験豊富であると考えられます ( 4.4年の平均在任期間)。

Aptahem マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Aptahem AB (publ), Annual General Meeting, May 15, 2024

Aptahem AB (publ), Annual General Meeting, Jun 01, 2023

No independent directors

Aptahem (Publ) Announces Executive Changes

No independent directors

Aptahem Appoints Karin Aschan as New Regulatory Affairs Director

Recent updates

Aptahem AB (publ) Reports the FIH Study on Apta-1 Has Been Finalized

First quarter 2024 earnings released

Aptahem AB (publ) to Report Q3, 2024 Results on Jun 19, 2024

Aptahem Plans to Perform A Proof-Of-Concept Phase 2 Study in Patients with Its Lead Candidate Apta-1

Aptahem Reports Top Line Results from the Fih Study with Apta-1

New major risk - Shareholder dilution

Aptahem AB (publ), Annual General Meeting, May 15, 2024

Full year 2023 earnings released: kr0.058 loss per share (vs kr0.053 loss in FY 2022)

Aptahem AB (publ) Reports Promising Outcome from the Additional Analyses on the Mechanism on Lead Candidate Apta-1 in the FIH Study

Second quarter 2023 earnings released

Aptahem AB (publ) Announces in Aptahem's FIH Study Further Analytic Studies Will Be Performed

Aptahem AB (publ) to Report Nine Months, 2023 Results on Oct 26, 2023

Aptahem AB (Publ) Announces the Completion of an Additional Cohort in the Ongoing Double-Blinded Randomized Placebo Controlled Clinical First in Human Study

Dutch Ethics Committee Approves Aptahem AB (Publ)'s Second Dose Cohort in the Clinical First in Human Study in Healthy Volunteers

Aptahem AB (publ), Annual General Meeting, Jun 01, 2023

Aptahem AB (publ) Announces First Cohort Dosed in Aptahem's FIH Study

Aptahem AB (Publ), Announces First Subjects Dosed in Fih Study

Aptahem AB (publ) Announces First Subjects Screened in Aptahem's FIH Study with Apta-1

Aptahem Reports Added Positive and Significant Biological Effect in an Extended Corona Virus-Induced Acute Lung Injury Model Treated with Apta-1

No independent directors

Aptahem AB (publ) Receives Full Regulatory Approval to Start the FIH Study with Apta-1

Aptahem AB (publ) Submit Regulatory Approval to Initiate Clinical Phase 1 Study

Aptahem AB (publ) Confirms Lead Candidate Apta-1 Shows Very Good Tolerability in GLP Tox Studies

Aptahem (Publ) Announces Executive Changes

No independent directors

Aptahem AB (publ) Reports Additional Positive Biological Effect in A Corona Virus-Induced Acute Lung Injury Model Treated with Apta-1

Aptahem Appoints Karin Aschan as New Regulatory Affairs Director

Aptahem AB (Publ) Appoints Thomas Rupp as CMC Director

Aptahem AB (publ) Receives Intention to Grant from the European Patent Office for the Protection of Patent Family 2

Aptahem AB (Publ) Receives Notice of Allowance from the US Patent Office

Aptahem Signs A Non Binding Term Sheet for Development, Manufacturing and Distribution of Apta-1 for Sepsis in Europe

Aptahem AB (publ) Signs Agreement with Collaboration Partner LGC Group to Initiate the GMP Manufacturing of Apta-1

New 90-day low: kr1.30

New 90-day low: kr1.33

Aptahem AB (publ) to Report Fiscal Year 2020 Final Results on Apr 08, 2021

New 90-day low: kr1.38

New 90-day low: kr1.39

New 90-day low: kr1.61

New 90-day low: kr1.76

Aptahem AB (publ) to Report Q3, 2020 Results on Nov 30, 2020

New 90-day low: kr2.07

New 90-day low - kr2.07

First half earnings released

New 90-day high - kr3.18

CEO（最高経営責任者

在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14